Cytek Biosciences, Inc. (CTKB) Stock Forecast
CTKB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.75 / 5 from 4 analysts
- Price target
- $5.56 average of analyst targets
- Upside to target
- +6.0% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.05
- 52-week range
- $3.35 – $6.09
CTKB analyst ratings
4 analystsNumber of analysts at each rating.
CTKB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CTKB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.07 | −$0.08 | −$0.06 | −$0.04 | −75.0% | 2 |
| Current fiscal year (2026) | −$0.12 | −$0.12 | −$0.12 | −$0.31 | +61.7% | 1 |
| Next fiscal year (2027) | $0.07 | $0.07 | $0.07 | −$0.12 | +158.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CTKB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $52.9M | $52.7M | $53.2M | +1.2% | 3 |
| Current fiscal year (2026) | $209.4M | $209.0M | $210.1M | +3.9% | 4 |
| Next fiscal year (2027) | $223.2M | $217.1M | $226.6M | +6.6% | 4 |
CTKB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CTKB revenue: reported and forecast
CTKB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.07 | −$0.07 | −$0.07 | −$0.07 | +16.7% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.13 | −$0.04 | −$0.04 | −$0.03 | −$0.12 | −7.7% | 0 up · 1 down |
| Next fiscal year (2027) | $0.06 | $0.19 | $0.19 | $0.20 | $0.07 | +16.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CTKB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CTKB beat in 7 of 12.
What analysts expect from CTKB
4 analysts cover Cytek Biosciences; their consensus rating is buy (3.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.56, 6.0% above the latest close of $5.25. Analysts expect earnings of −$0.12 per share for 2026, +61.7% from a year earlier. For 2027 the average estimate is $0.07 per share on revenue of $223.2 million. Cytek Biosciences beat the EPS estimate in 7 of the last 12 quarters.
Related: CTKB income statement, CTKB key metrics, CTKB chart. See the CTKB stock overview for the latest quote and news.
CTKB forecast FAQ
What is Cytek Biosciences's price target?
The average analyst price target for Cytek Biosciences is $5.56, 6.0% above the latest close of $5.25.
Is Cytek Biosciences a buy, hold or sell?
Of 4 analysts covering Cytek Biosciences, 1 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cytek Biosciences's EPS forecast?
Analysts forecast −$0.12 per share for 2026 (range −$0.12 to −$0.12); for 2027 the estimate is $0.07.
What is Cytek Biosciences's revenue forecast?
The average revenue estimate for 2026 is $209.4 million, growth of 3.9%; for 2027 it is $223.2 million.
When does Cytek Biosciences report earnings?
Cytek Biosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.05.
Does Cytek Biosciences usually beat earnings estimates?
Cytek Biosciences reported EPS at or above the analyst estimate in 7 of the last 12 quarters.